Scott E. Eggener to United States
This is a "connection" page, showing publications Scott E. Eggener has written about United States.
Connection Strength
1.217
-
Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
Score: 0.078
-
National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
Score: 0.077
-
Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252.
Score: 0.072
-
Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. Eur Urol Oncol. 2018 12; 1(6):501-506.
Score: 0.068
-
Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288.
Score: 0.063
-
Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032.
Score: 0.063
-
Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. J Urol. 2017 03; 197(3 Pt 1):684-689.
Score: 0.060
-
National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. J Urol. 2016 May; 195(5):1383-1389.
Score: 0.057
-
Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82.
Score: 0.055
-
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23.
Score: 0.055
-
Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7.
Score: 0.053
-
National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102.
Score: 0.052
-
Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May; 33(5):623-31.
Score: 0.052
-
Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91.
Score: 0.052
-
Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.
Score: 0.050
-
National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.
Score: 0.050
-
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4.
Score: 0.044
-
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43.
Score: 0.041
-
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779.
Score: 0.020
-
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119.
Score: 0.018
-
Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.
Score: 0.017
-
African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81.
Score: 0.016
-
Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397.
Score: 0.015
-
Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94.
Score: 0.013
-
Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.
Score: 0.013
-
Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.
Score: 0.013
-
Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014 Aug 10; 32(23):2471-8.
Score: 0.013
-
Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8.
Score: 0.013
-
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28.
Score: 0.008
-
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.
Score: 0.008
-
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.
Score: 0.008